gsgs
Registered User
http://www.healthemergency.gov.au/internet/healthemergency/publishing.nsf/Content/ozflu2009.htm/$File/ozflu-no20-2009.pdf
179 deaths from ****** in Australia 19.June-25.Sept
median age = 51y (seasonal: 83y)
median age = 21y for all confirmed cases, 31y for hospitalised cases; 43y for ICU cases,53 y for deaths.
estimates for Western Australia:
P+I deaths are 14.5% of all deaths in late August
------------------------------------------------------------------------
CAR for Victoria =5% (21.July)
use of the FluAid 2.0 model ... first 10 weeks ... in Victoria.
5% gross clinical attack rate,
0.3% of these hospitalised
20% of these transfered to ICUs
15% of these died
http://www.mja.com.au/public/issues/191_09_021109/lum10916_fm.html
--------------------------------------------------------------------
The clinical attack rate refers to the number of people infected with pandemic (H1N1) 2009 influenza who needed any form of clinical assessment or care. The 5% clinical attack rate observed in Victoria is well below the level assumed in the Australian Health Management Plan for Pandemic Influenza.10 This reflects the mild nature of the disease at present. The community attack rate is likely to have been much higher, with most cases being subclinical or minimally symptomatic. Evidence from a serological survey to determine the community attack rates will be needed as soon as is practicable
------------------------------------------------------------
http://ecdc.europa.eu/en/activities...t=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&ID=650
...
serological work around the recent Australian vaccine trial which found surprisingly high levels
of antibody in the baseline samples from people who had been thought not to have been infected
in the A(H1N1) 2009 epidemics, a much higher level than seen in the baseline in the trial undertaken
in Europe and consistent with more widespread asymptomatic infection in Australia than expected.
http://content.nejm.org/cgi/content/full/NEJMoa0907413
From July 22 to July 26, 2009, we enrolled 240 subjects in Australia
45.0% had got seasonal vax.
76 of the 240 subjects (31.7%) had antibody titers of 1:40 or more on HI, with no significant
differences between age groups.
baseline titers of 1:40 or more on HI in 48 of 108 who had got the 2009 seasonal vax
and in 28 of 132 who not
Post-vax titers of 1:40 or more in 96.7% (15myg)
Seroconversion in 74.2%
--------------------------------------------------------------------------------------------
http://content.nejm.org/cgi/content/full/NEJMoa0907650
single-center, phase 1, randomized study from July through September 2009 at
Leicester Royal Infirmary (Leicester, United Kingdom).
median age = 33y, 65% female, 82% white, 37% had previously received seasonal vax
9% had seroprotection before vaccination, 83% after one dose of Novartis MF59-vaccine
-------------------------------------------------------------------------------------------
179 deaths from ****** in Australia 19.June-25.Sept
median age = 51y (seasonal: 83y)
median age = 21y for all confirmed cases, 31y for hospitalised cases; 43y for ICU cases,53 y for deaths.
estimates for Western Australia:
P+I deaths are 14.5% of all deaths in late August
------------------------------------------------------------------------
CAR for Victoria =5% (21.July)
use of the FluAid 2.0 model ... first 10 weeks ... in Victoria.
5% gross clinical attack rate,
0.3% of these hospitalised
20% of these transfered to ICUs
15% of these died
http://www.mja.com.au/public/issues/191_09_021109/lum10916_fm.html
--------------------------------------------------------------------
The clinical attack rate refers to the number of people infected with pandemic (H1N1) 2009 influenza who needed any form of clinical assessment or care. The 5% clinical attack rate observed in Victoria is well below the level assumed in the Australian Health Management Plan for Pandemic Influenza.10 This reflects the mild nature of the disease at present. The community attack rate is likely to have been much higher, with most cases being subclinical or minimally symptomatic. Evidence from a serological survey to determine the community attack rates will be needed as soon as is practicable
------------------------------------------------------------
http://ecdc.europa.eu/en/activities...t=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&ID=650
...
serological work around the recent Australian vaccine trial which found surprisingly high levels
of antibody in the baseline samples from people who had been thought not to have been infected
in the A(H1N1) 2009 epidemics, a much higher level than seen in the baseline in the trial undertaken
in Europe and consistent with more widespread asymptomatic infection in Australia than expected.
http://content.nejm.org/cgi/content/full/NEJMoa0907413
From July 22 to July 26, 2009, we enrolled 240 subjects in Australia
45.0% had got seasonal vax.
76 of the 240 subjects (31.7%) had antibody titers of 1:40 or more on HI, with no significant
differences between age groups.
baseline titers of 1:40 or more on HI in 48 of 108 who had got the 2009 seasonal vax
and in 28 of 132 who not
Post-vax titers of 1:40 or more in 96.7% (15myg)
Seroconversion in 74.2%
--------------------------------------------------------------------------------------------
http://content.nejm.org/cgi/content/full/NEJMoa0907650
single-center, phase 1, randomized study from July through September 2009 at
Leicester Royal Infirmary (Leicester, United Kingdom).
median age = 33y, 65% female, 82% white, 37% had previously received seasonal vax
9% had seroprotection before vaccination, 83% after one dose of Novartis MF59-vaccine
-------------------------------------------------------------------------------------------
